Joseph Jankovic1, Charles H Adler2, David Charles3, Cynthia Comella4, Mark Stacy5, Marc Schwartz6, Aubrey Manack Adams7, Mitchell F Brin8. 1. Baylor College of Medicine, Houston, TX, USA. Electronic address: josephj@bcm.edu. 2. Mayo Clinic Arizona, Scottsdale, AZ, USA. 3. Vanderbilt University Medical Center, Nashville, TN, USA. 4. Rush University Medical Center, Chicago, IL, USA. 5. Duke University Medical Center, Durham, NC, USA. 6. MedNet Solutions, Inc., Minnetonka, MN, USA. 7. Allergan, Inc., Irvine, CA, USA. 8. Allergan, Inc., Irvine, CA, USA; University of California, Irvine, CA, USA.
Abstract
BACKGROUND: The Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE; NCT00836017) is a prospective, observational, multicenter, real-world registry designed to assess the safety, effectiveness, and treatment utilization following multiple treatments of onabotulinumtoxinA. METHODS: Subjects were naïve to botulinum toxin, new to practice, or had not received toxin in ≥ 16 weeks if in a clinical trial. Dosages and treatment intervals varied due to the real-world design. Descriptive and inferential statistics evaluated changes over 3 treatments. RESULTS: 1046 subjects enrolled. Subjects were 74.4% female, 63.5% toxin-naïve, mean age 58.0 ± 14.7 years. The mean dose over 2481 treatment sessions was 189. 8 ± 87.1U, with average treatment intervals of 14.6 and 15.1 weeks. The mean Toronto Western Spasmodic Torticollis Rating Scale Total score in subjects who completed all assessments (n=479) decreased from 39.2 at baseline to 27.1 at final visit (P<.0001). A high percentage of physicians reported improvement in Clinician Global Impression of Change after initial assessment; this significantly increased at final assessment (n=479, 91.2% vs 95.0%; P<.0001). Similarly, a high percentage of subjects reported improvement in Patient Global Impression of Change after initial assessment, which significantly increased at final assessment (n=470, 83.0% vs 91.7%; P<.0001). Significant reductions in all Cervical Dystonia Impact Profile-58 scores were observed (n=407). Overall, 26.2% of subjects reported adverse events, including muscular weakness (7.0%) and dysphagia (6.4%). CONCLUSIONS: Results indicate robust improvement in clinical ratings and excellent tolerability following onabotulinumtoxinA treatment of CD.
BACKGROUND: The Cervical DystoniaPatient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE; NCT00836017) is a prospective, observational, multicenter, real-world registry designed to assess the safety, effectiveness, and treatment utilization following multiple treatments of onabotulinumtoxinA. METHODS: Subjects were naïve to botulinum toxin, new to practice, or had not received toxin in ≥ 16 weeks if in a clinical trial. Dosages and treatment intervals varied due to the real-world design. Descriptive and inferential statistics evaluated changes over 3 treatments. RESULTS: 1046 subjects enrolled. Subjects were 74.4% female, 63.5% toxin-naïve, mean age 58.0 ± 14.7 years. The mean dose over 2481 treatment sessions was 189. 8 ± 87.1U, with average treatment intervals of 14.6 and 15.1 weeks. The mean Toronto Western Spasmodic Torticollis Rating Scale Total score in subjects who completed all assessments (n=479) decreased from 39.2 at baseline to 27.1 at final visit (P<.0001). A high percentage of physicians reported improvement in Clinician Global Impression of Change after initial assessment; this significantly increased at final assessment (n=479, 91.2% vs 95.0%; P<.0001). Similarly, a high percentage of subjects reported improvement in Patient Global Impression of Change after initial assessment, which significantly increased at final assessment (n=470, 83.0% vs 91.7%; P<.0001). Significant reductions in all Cervical Dystonia Impact Profile-58 scores were observed (n=407). Overall, 26.2% of subjects reported adverse events, including muscular weakness (7.0%) and dysphagia (6.4%). CONCLUSIONS: Results indicate robust improvement in clinical ratings and excellent tolerability following onabotulinumtoxinA treatment of CD.
Authors: David M Simpson; Mark Hallett; Eric J Ashman; Cynthia L Comella; Mark W Green; Gary S Gronseth; Melissa J Armstrong; David Gloss; Sonja Potrebic; Joseph Jankovic; Barbara P Karp; Markus Naumann; Yuen T So; Stuart A Yablon Journal: Neurology Date: 2016-04-18 Impact factor: 9.910
Authors: A R Bentivoglio; E Di Stasio; D Mulas; M L Cerbarano; T Ialongo; A Laurienzo; Martina Petracca Journal: Neurotox Res Date: 2017-05-06 Impact factor: 3.911
Authors: Martina Petracca; Maria Rita Lo Monaco; Tamara Ialongo; Enrico Di Stasio; Maria Luana Cerbarano; Loredana Maggi; Alessandro De Biase; Giulia Di Lazzaro; Paolo Calabresi; Anna Rita Bentivoglio Journal: J Neurol Date: 2022-09-06 Impact factor: 6.682
Authors: Pinky Agarwal; Richard Barbano; Henry Moore; Marc Schwartz; Aleksej Zuzek; Marjan Sadeghi; Atul Patel Journal: Front Neurol Date: 2022-06-30 Impact factor: 4.086
Authors: Jeanne P Vu; Ha Yeon Lee; Qiyu Chen; Elizabeth Cisneros; Richard L Barbano; Christopher G Goetz; Joseph Jankovic; Hyder A Jinnah; Joel S Perlmutter; Brian D Berman; Mark I Appelbaum; Glenn T Stebbins; Cynthia L Comella; David A Peterson Journal: J Neurol Date: 2021-01-08 Impact factor: 4.849